Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

United Therapeutics Corporation - Common Stock (NQ:UTHR)

300.16 -0.40 (-0.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of... 
Via StockStory
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Scheduled For April 30, 2025
Via Benzinga
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Via Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire
How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles?
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fits the characteristics of a... 
Via Chartmill
2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
Why Quality Investors May Find UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Attractive.
A fundamental analysis of (NASDAQ:UTHR): Is UNITED THERAPEUTICS CORP (NASDAQ:UTHR) a Strong Candidate for Quality Investing? 
Via Chartmill
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
3 Reasons Investors Watch United Therapeutics (UTHR)
Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results... 
Via StockStory
Topics Stocks
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy
With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put UNITED THERAPEUTICS CORP (NASDAQ:UTHR) to the test against his... 
Via Chartmill
2 Value Stocks on Our Watchlist and 1 to Ignore
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
From United Therapeutics Corporation
Via Business Wire
Why United Therapeutics (UTHR) Stock Is Down Today
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations,... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations
Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was... 
Via StockStory
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%. 
Via StockStory
Topics Stocks
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.